AU2022260529A1 - Compounds for use in the treatment of hyperproliferative disorders - Google Patents
Compounds for use in the treatment of hyperproliferative disorders Download PDFInfo
- Publication number
- AU2022260529A1 AU2022260529A1 AU2022260529A AU2022260529A AU2022260529A1 AU 2022260529 A1 AU2022260529 A1 AU 2022260529A1 AU 2022260529 A AU2022260529 A AU 2022260529A AU 2022260529 A AU2022260529 A AU 2022260529A AU 2022260529 A1 AU2022260529 A1 AU 2022260529A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- thiazol
- indol
- methyl
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382343.8 | 2021-04-21 | ||
| EP21382343.8A EP4079304A1 (en) | 2021-04-21 | 2021-04-21 | Compounds for use in the treatment of hyperproliferative disorders |
| PCT/EP2022/060579 WO2022223704A1 (en) | 2021-04-21 | 2022-04-21 | Compounds for use in the treatment of hyperproliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022260529A1 true AU2022260529A1 (en) | 2023-11-09 |
Family
ID=75674747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022260529A Pending AU2022260529A1 (en) | 2021-04-21 | 2022-04-21 | Compounds for use in the treatment of hyperproliferative disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240208998A1 (https=) |
| EP (2) | EP4079304A1 (https=) |
| JP (1) | JP2024515705A (https=) |
| KR (1) | KR20240013112A (https=) |
| CN (1) | CN117320715A (https=) |
| AU (1) | AU2022260529A1 (https=) |
| BR (1) | BR112023021959A2 (https=) |
| CA (1) | CA3216090A1 (https=) |
| IL (1) | IL307868A (https=) |
| MX (1) | MX2023012457A (https=) |
| WO (1) | WO2022223704A1 (https=) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2609912T3 (es) * | 2007-06-22 | 2017-04-25 | Hydra Biosciences, Inc. | Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1 |
-
2021
- 2021-04-21 EP EP21382343.8A patent/EP4079304A1/en not_active Withdrawn
-
2022
- 2022-04-21 CN CN202280035450.7A patent/CN117320715A/zh active Pending
- 2022-04-21 BR BR112023021959A patent/BR112023021959A2/pt unknown
- 2022-04-21 US US18/556,456 patent/US20240208998A1/en active Pending
- 2022-04-21 EP EP22723682.5A patent/EP4326262A1/en active Pending
- 2022-04-21 JP JP2023564537A patent/JP2024515705A/ja active Pending
- 2022-04-21 KR KR1020237040063A patent/KR20240013112A/ko active Pending
- 2022-04-21 WO PCT/EP2022/060579 patent/WO2022223704A1/en not_active Ceased
- 2022-04-21 IL IL307868A patent/IL307868A/en unknown
- 2022-04-21 MX MX2023012457A patent/MX2023012457A/es unknown
- 2022-04-21 AU AU2022260529A patent/AU2022260529A1/en active Pending
- 2022-04-21 CA CA3216090A patent/CA3216090A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024515705A (ja) | 2024-04-10 |
| WO2022223704A1 (en) | 2022-10-27 |
| IL307868A (en) | 2023-12-01 |
| MX2023012457A (es) | 2023-11-22 |
| EP4079304A1 (en) | 2022-10-26 |
| CA3216090A1 (en) | 2022-10-27 |
| KR20240013112A (ko) | 2024-01-30 |
| US20240208998A1 (en) | 2024-06-27 |
| BR112023021959A2 (pt) | 2023-12-26 |
| CN117320715A (zh) | 2023-12-29 |
| EP4326262A1 (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1326865B1 (en) | Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors | |
| CN102816175B (zh) | 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途 | |
| US6919351B2 (en) | Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors | |
| JP5282026B2 (ja) | テトラヒドロピリドチエノピリミジン化合物およびその使用法 | |
| KR20180086221A (ko) | Ror-감마의 조절물질 | |
| EP3642184A1 (en) | Small molecule modulators of human sting | |
| WO2005095419A1 (ja) | チアゾロピリミジン誘導体 | |
| CA2425625A1 (en) | Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors | |
| JP2016517857A (ja) | 置換５−（３，５−ジメチルイソオキサゾール−４−イル）インドリン−２−オン | |
| CA2195697A1 (en) | Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof | |
| CN105683195A (zh) | 新的喹啉取代的化合物 | |
| WO2018233553A1 (zh) | 稠合双环类化合物及其在药物中的应用 | |
| CN115448921B (zh) | 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途 | |
| US9156853B2 (en) | AKT inhibitor compounds for treatment of cancer | |
| CN104926801A (zh) | 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用 | |
| WO2025007801A1 (zh) | 一种嘌呤类衍生物及其用途 | |
| KR101754664B1 (ko) | 치환된 피리도〔2,3-ｄ〕피리미딘-7(8ｈ)-온스 및 이의 치료 용도 | |
| WO2019034178A1 (zh) | 一种dna毒性二聚体化合物 | |
| CN112300154B (zh) | 一类含氮杂环化合物、其制备方法和用途 | |
| EP4326262A1 (en) | Compounds for use in the treatment of hyperproliferative disorders | |
| WO2007022241A2 (en) | Novel high affinity quinoline-based kinase ligands | |
| EA048831B1 (ru) | Соединения для применения при лечении гиперпролиферативных заболеваний | |
| KR20190071718A (ko) | 돌연변이체 이소시트레이트 탈수소효소 억제제 및 그 조성물 및 그 제조방법 | |
| Zhang et al. | Synthesis and biological evaluation of novel 1, 2, 3-benzotriazin-4-one derivatives as leukotriene A4 hydrolase aminopeptidase inhibitors | |
| WO2021206955A1 (en) | Macrocyclic compounds as kinases inhibitors and uses thereof |